News | October 09, 2024
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
Strategic focus on COCO-model with a nationwide reach of 501 stores
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Poor oral health (periodontal disease) impacts nearly 51% of Indians
Emcure will play a crucial role in ensuring the availability of high-quality, low-cost versions of lenacapavir in 120 countries
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
The Lilly Medicine Foundry is set to drive innovation in drug production and make medicines for clinical trials
Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules
Subscribe To Our Newsletter & Stay Updated
